Get started
Live feed
·
PRReleasevia Quantisnow
Alzamend Neuro Inc. logo

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for ALZN

Across the 6 sessions after earlier ALZN headlines, the stock closed higher 3 times and lower 3 times, with a median move of 5.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

ALZN close-to-close change in the session after earlier headlines
SessionEarlier headlineALZNSPY
Aug 20, 2026Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC+7.2%-0.8%
Aug 18, 2026Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain-3.8%-0.7%
Aug 4, 2026Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending+8.2%+1.8%
Apr 7, 2026Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital-2.5%+0.0%
Mar 26, 2026Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions-22.3%-1.8%
Mar 16, 2026Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital+2.9%+1.0%
Quantisnow market dataNASDAQ
Alzamend Neuro Inc. logo
ALZN
Alzamend Neuro Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Listed since
2021
Get push alerts for ALZN

Follow ALZN and get a push notification the moment its next story breaks.

Full ALZN profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALZN (Alzamend Neuro Inc.) and more on Quantisnow.